BioMarin Pharmaceuticals
BMRN
BMRN
557 hedge funds and large institutions have $15.5B invested in BioMarin Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 68 funds opening new positions, 198 increasing their positions, 192 reducing their positions, and 59 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
0.41% less ownership
Funds ownership: 95.62% → 95.21% (-0.41%)
6% less call options, than puts
Call options by funds: $148M | Put options by funds: $158M
11% less capital invested
Capital invested by funds: $17.4B → $15.5B (-$1.91B)
Holders
557
Holding in Top 10
11
Calls
$148M
Puts
$158M
Top Buyers
| 1 | +$187M | |
| 2 | +$99.4M | |
| 3 | +$46.7M | |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$41.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$33.8M |
Top Sellers
| 1 | -$78.4M | |
| 2 | -$69.3M | |
| 3 | -$58.6M | |
| 4 |
Jennison Associates
New York
|
-$46.7M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
-$42.6M |